Disposition and biotransformation of the antiretroviral drug nevirapine in humans

Drug Metabolism and Disposition

Volumn 27, Issue 8, 1999, Pages 895-901

  Riska, Paul ^a   Lamson, Michael ^a   Macgregor, Thomas ^a   Sabo, John ^a   Hattox, Susan ^a   Pav, Joseph ^a   Keirns, James ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; NEVIRAPINE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; HALF-LIFE; HUMANS; HYDROLYSIS; MALE; MASS SPECTROMETRY; NEVIRAPINE; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION;

EID: 0032770872     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Cheeseman S, Havlir D and McLaughlin MM (1995) Phase I/II evaluation of NVP alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 8:141-151.
2. Havlir D, Cheeseman SH, McLaughlin MM, Murphy R, Alejo E, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M and Richman DD (1995) High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537-545.
3. Lamson MJ, Cort S, Sabo JP and Keims JJ (1995a) Assessment of nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharmacol Res 12:S-415.
4. Lamson MJ, Cort S, Sabo JP, MacGregor TR and Keims JJ (1995b) Effects of gender on the single and multiple dose pharmacokinetics of nevirapine. Pharmacol Res 12:S-101.
5. Merluzzi KD, Hargrave K, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA and Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (Wash DC) 250:1411-1413.
6. Murphy RL and Montaner J (1996) Nevirapine: A review of its development, pharmacological profile and potential for clinical use. Exp Opin Inves Drugs 5:1183-1199.
7. Murphy R. Sommadossi JP, Lamson MJ, Hall D, Myers M and Dusek A (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in HIV-1 infected individuals. J Infect Dis 179:1116-1123.
8. Richman D, Rosenthal AS, Skoog M, Eckner RJ, Sabo JP and Merluzzi VJ (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type I and synergizes with zidovudine. Antimicrob Agents Chemother 35:305-308.
9. Riska PS, Joseph DP, Dinallo RP and Keims JJ (1996) Metabolism of nevirapine, a nonnucleoside reverse transcriptase inhibitor, in mouse, rat, dog, rabbit and monkey. ISSX Proceedings 10:299.
10. Sahai J, Cameron W, Salgo M, Stewart F, Myers Lamson MJ and Gagnier P (1997) Drug interaction study between saquinavir and nevirapine (Abstract). Int Conf AIDS (abstract no. 614) 4:178.